---
title: "Verastem Inc. to Participate in Cantor Global Healthcare Conference 2025"
description: "Verastem Inc., a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, will participate in the Cantor Global Healthcare Conference 2025. The management team is scheduled to present dur"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254788996.md"
published_at: "2025-08-27T11:00:31.000Z"
---

# Verastem Inc. to Participate in Cantor Global Healthcare Conference 2025

> Verastem Inc., a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, will participate in the Cantor Global Healthcare Conference 2025. The management team is scheduled to present during a fireside chat on September 3 at 3:55 pm ET. This announcement was generated by Public Technologies and is for informational purposes only.

Verastem Inc., a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, is set to participate in the Cantor Global Healthcare Conference 2025. The company’s management team will present during a fireside chat on Wednesday, September 3, at 3:55 pm ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250827486598) on August 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [VSTM.US - Verastem](https://longbridge.com/en/quote/VSTM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Verastem Grants Stock Options and Restricted Stock Units to New Employees | Verastem Oncology has granted stock options for 73,000 shares and 218,265 restricted stock units to new employees. The s | [Link](https://longbridge.com/en/news/272317501.md) |
| Guggenheim Keeps Their Buy Rating on Verastem (VSTM) | Guggenheim analyst maintained a Buy rating on Verastem yesterday and set a price target of $14.00. The company’s shares  | [Link](https://longbridge.com/en/news/269863920.md) |
| Verastem, Inc Discontinues RAMP 203 Clinical Trial | Verastem, Inc. has announced the discontinuation of the RAMP 203 clinical trial for advanced KRAS G12C-mutated NSCLC as  | [Link](https://longbridge.com/en/news/271206614.md) |
| Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC | Verastem Oncology has halted its RAMP 203 Phase 1⁄2 trial for avutometinib in advanced KRAS G12C-mutated NSCLC to focus  | [Link](https://longbridge.com/en/news/271029259.md) |
| Verastem CEO Dan Paterson Reports Sale of Common Shares | Dan Paterson, CEO of Verastem Inc., reported the sale of common shares. The information was published via EDGAR by Veras | [Link](https://longbridge.com/en/news/269572307.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.